Influence of two different escherichia coli asparaginase preparations on fibrinolytic proteins in childhood all

Haematologica

Volumn 81, Issue 2, 1996, Pages 127-131

  Nowak Göttl, Ulrike ^a   Werber, Gisela ^a   Ziemann, Detlef ^a   Ahlke, Elvira ^a   Boos, Joachim ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

2 antiplasmin; Asparaginase activity; Childhood ALL; PAI 1; Plasminogen; t PA

Indexed keywords

ASPARAGINASE; FIBRINOGEN; MEDAC; PLASMINOGEN; PREDNISOLONE; PROTHROMBIN; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COMORBIDITY; DRUG EFFECT; FIBRINOGEN BLOOD LEVEL; FIBRINOLYTIC THERAPY; HEMOSTASIS; HUMAN; THROMBOSIS; TREATMENT PLANNING; VEIN PUNCTURE;

ANTINEOPLASTIC AGENTS; ASPARAGINASE; BLOOD PROTEINS; CHILD; ESCHERICHIA COLI; FIBRINOLYSIS; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; NEOPLASM PROTEINS; PROSPECTIVE STUDIES;

EID: 0030326241     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Semeraro N, Montemurro P, Giordano P, et al. Unbalanced coagulation-fibrinolysis potential during L-asparaginase therapy in children with acute lymphoblastic leukemia. Thromb Haemost 1990; 64:38-40.
2. Leone G, Gugliotta L, Mazzucconi MG, et al. Evidence of a hypercoagulable state in patients with acute lymphoblastic leukemia treated with low doses of E. coli asparaginase. A GIMEMA study. Thromb Haemost 1993; 69:12-5.
3. Kucuk O, Kwaan HC, Gunnar W, Wasquez RM. Thromboembolic complications associated with L-asparaginase therapy. Cancer 1985; 55:702-6.
4. Homans AC, Rybak ME, Baglini RL, Tiarks C, Steiner ME, Forman EN. Effect of L-asparaginase administration on coagulation and platelet function in children with leukemia. J Clin Oncol 1987; 5:811-7.
5. Pui CH, Jackson CW, Chesney CM, Abilgaard CF. Involvement of von Willebrand factor in thrombosis following asparaginase-prednison-vincristine therapy for leukemia. Am J Hematol 1987; 25:291-8.
6. Mitchell L, Hoogendoorn H, Giles AR, et al. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: risk of thrombotic complications in L asparaginase-induced antithrombm III deficiency. Blood 1994; 83:386-91.
7. Nowak-Göttl U, WolfF J, Kuhn N, et al. Enhanced thrombin generation, P-VonWillebrand factor, P-fibrin, D-dimer and P-plasminogcn activator inhibitor 1: predictive for venous thrombosis in asparaginase-treated children. Fibrinolysis 1994; 8:63-5.
8. Capizzi R, Holcinberg JS. L-asparaginase. In: Holland J, Frei E, eds. Cancer Medicine. Philadelphia:Lea & Febiger 1992:796.
9. Ohnuma T, Holland JF, Freemann A, et al. Biochemical and pharmacological studies with asparaginase in man. Cancer Res 1979; 30:2297-305.
10. Wriston IC, Yellin TO. L asparaginase: a review. Advanced Enzymol Relat Areas Mol Biol 1973; 39:185-248.
11. Bergemeyer HU. Methoden der enzymatischen Analyse. L-Asparaginase. 3. überarbeitete und erweiterte Auflage. Verlag Chemie 1974; 11:464-5.
12. Werber G, Ahlke E, Nowak-Gottl U, Jurgens H, Verspohl EJ, Boos J. Asparaginase activities are highly sensitive to different buffer conditions. In: Büchner T, Hiddemann W, Wornemann B, Ritter O, eds. Haematology and Blood Transfusion, v. 38; Berlin:Springer Verlag, 1996; in press.
13. Lenda K, Svenneby G. Rapid high-performance liquid chromatographic determination of amino acids in synaptosomal abstracts. Chrom 1980; 198:516-9.
14. Nowak-Gottl U, Kuhn N, Wolff JEA, et al. Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase -treated children. Eur J Haematol 1995; in press.
15. Nowak-Göttl U, Rath B, Binder M, et al. Inefficacy of fresh frozen plasma in the treatment of L-asparaginase- induced coagulation factor deficiencies during ALL induction therapy. Haematologica 1995; 80:451-3.
16. Arens A, Rauenbusch E, Iron E, Wagner O, Bauer K, Kaufmann WZ. Physiol Chem 1970; 351:197.
17. Boos J, Nowak-Götti U, Jürgens H, Fleischhack G, Bode U. Loss of activity of Erwinia asparaginase on repeat applications. J Clin Oncol 1995; 13:2474-5.
18. Boos J, Werber G, Ahlke E, Nowak-Göttl U, Verspohl E, Jürgens H. Significant differences in the pharmacokinetics of two 1-asparaginase preparations from Escherichia Coli. In: Büchner T, Hiddemann W, Wornemann B, Ritter O, eds. Haematology and Blood Transfusion, Berlin:Springer Verlag, 1995; in press.
19. Mashburn LT, Landin LM. In: Grundmann E, Oettgen HF, eds. Recent results in cancer research. New York:Springer, 1970:33-48.